APO-PROPRANOLOL 120 MG
PROPRANOLOL HYDROCHLORIDE : 120 MG · DIN 00504335 · APOTEX INC
Health Canada status: DORMANT
What is APO-PROPRANOLOL?
APO-PROPRANOLOL 120 MG contains PROPRANOLOL HYDROCHLORIDE : 120 MG. It is listed in the Health Canada Drug Product Database under DIN 00504335, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 29-Jan-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-PROPRANOLOL used for?
Hypertension, prophylaxis of angina pectoris, cardiac arrhythmias, prophylaxis of migraine, hypertrophic subaortic stenosis, and adjunctive therapy in pheochromocytoma.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00504335 |
|---|---|
| Brand name | APO-PROPRANOLOL |
| Generic / active ingredient | PROPRANOLOL HYDROCHLORIDE : 120 MG |
| Manufacturer | APOTEX INC |
| Strength | 120 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C07AA05 PROPRANOLOL |
| AHFS class | 24:24.00 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 29-Jan-2021 |
| Original market date | 1981-12-31 00:00:00 |
How is it administered?
Dosage must be individualized. For hypertension/angina, usually started at low doses and increased gradually. Abrupt cessation must be avoided; taper over 2 weeks.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text.
How is it supplied?
Not explicitly detailed in the provided text (mentions 10, 20, 40, 80 and 120 mg tablets).
Contraindications
Bronchospasm, asthma, allergic rhinitis, sinus bradycardia, >1st degree block, cardiogenic shock, heart failure, hypoglycemia-prone patients, hypotension, metabolic acidosis, Prinzmetal’s angina.
Warnings and precautions
Risk of cardiac failure; abrupt cessation can exacerbate angina or cause MI; may mask hypoglycemia/thyrotoxicosis signs; caution in surgery/anesthesia; risk of bronchospasm.
What can be used instead?
Other Canadian products sharing ATC code C07AA05 PROPRANOLOL. 13 of 56 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| HEMANGIOL | 3.75 MG | SOLUTION | PIERRE FABRE DERMO-COSMETIQUE CANADA INC | MARKETED | DIN 02457857 |
| LUPIN-PROPRANOLOL LA | 120 MG | CAPSULE (EXTENDED RELEASE) | LUPIN PHARMA CANADA LIMITED | MARKETED | DIN 02491915 |
| LUPIN-PROPRANOLOL LA | 160 MG | CAPSULE (EXTENDED RELEASE) | LUPIN PHARMA CANADA LIMITED | MARKETED | DIN 02491923 |
| LUPIN-PROPRANOLOL LA | 60 MG | CAPSULE (EXTENDED RELEASE) | LUPIN PHARMA CANADA LIMITED | MARKETED | DIN 02491893 |
| LUPIN-PROPRANOLOL LA | 80 MG | CAPSULE (EXTENDED RELEASE) | LUPIN PHARMA CANADA LIMITED | MARKETED | DIN 02491907 |
| PROPRANOLOL HYDROCHLORIDE INJECTION USP | 1 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02225883 |
| PRZ-PROPRANOLOL | 20 MG | TABLET | PHARMARIS CANADA INC | MARKETED | DIN 02550814 |
| PRZ-PROPRANOLOL | 40 MG | TABLET | PHARMARIS CANADA INC | MARKETED | DIN 02550822 |
| PRZ-PROPRANOLOL | 80 MG | TABLET | PHARMARIS CANADA INC | MARKETED | DIN 02550830 |
| TEVA-PROPRANOLOL | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00496480 |
Who else supplies PROPRANOLOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PROPRANOLOL appears in 157 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.